DJIA38904.04 307.06
S&P 5005204.34 57.13
NASDAQ16248.52 199.44
Russell 20002060.10 8.70
German DAX18163.94 -238.49
FTSE 1007911.16 -64.73
CAC 408061.31 -90.24
EuroStoxx 505013.35 -57.20
Nikkei 22538992.08 -781.06
Hang Seng16723.92 -1.18
Shanghai Comp3069.30 -5.66
KOSPI2714.21 -27.79
Bloomberg Comm IDX102.90 0.64
WTI Crude-fut91.17 0.01
Brent Crude-fut86.57 1.15
Natural Gas1.79 0.00
Gasoline-fut2.79 -0.01
Gold-fut2345.40 33.50
Silver-fut27.50 0.46
Platinum-fut940.60 -5.50
Palladium-fut1007.40 -23.60
Copper-fut423.60 1.85
Aluminum-spot1815.00 0.00
Coffee-fut212.50 5.75
Soybeans-fut1185.00 5.00
Wheat-fut567.25 11.00
Bitcoin67976.00 304.00
Ethereum USD3328.10 56.27
Litecoin98.71 0.69
Dogecoin0.18 0.00
EUR/USD1.0862 0.0007
USD/JPY151.72 -0.02
GBP/USD1.2678 0.0016
USD/CHF0.9044 -0.0014
USD IDX104.28 0.08
US 10-Yr TR4.4 0.091
GER 10-Yr TR2.406 0.007
UK 10-Yr TR4.064 -0.005
JAP 10-Yr TR0.771 -0.004
Fed Funds5.5 0
SOFR5.32 0

Sub Markets

Topics

Alternative Assets  + VC  | 
Artera Raise $90M for AI-Enabled Cancer Therapy

Artera Raise $90M for AI-Enabled Cancer Therapy

Artera, a CA-based startup that offers an AI-enabled test aimed at personalizing therapy for prostate cancer patients, has raised $90 million from technology and healthcare investors Johnson & Johnson, TIME Ventures, Koch Disruptive Technologies, Coatue, Walden Catalyst Ventures, The Factory, Breyer Capital and angel investors.

The company intends to use the funds to invest in the development of tests to support therapy personalization in other cancers.

Artera’s multimodal AI-powered test for prostate cancer patients, called ArteraAI Prostate Test, helps predict the potential benefits of therapy and a patient’s prognosis by analyzing the patient’s clinical data and biopsy images.

“The American Cancer Society estimates that more than 288,000 new cases of prostate cancer will arise in 2023, with more than 34,000 deaths. AI has given clinicians and patients a powerful weapon in the fight against this disease,” said Andre Esteva, co-founder and CEO of Artera.

Founded in 2015, Artera has now raised $135 million. The company was formerly known as Well Health and rebranded itself in October.

Connect

Inside The Story

Artera

About Joe Palmisano

Joe Palmisano is Editorial Director for Connect Money, where he brings nearly three decades experience of market insights as a financial journalist, analyst and senior portfolio manager for leading financial publications, advisory firms, and hedge funds. In his role as Editorial Director, Joe is responsible for the selection of content and creation of daily business news covering the financial markets, including Alternative Assets, Direct Investment and Financial Advisory services. Before joining Connect Money, Joe was a financial journalist for the Wall Street Journal, regularly publishing feature stories and trend pieces on the foreign exchange, global fixed income and equity markets. Joe parlayed his experience as a financial journalist into roles as a Senior Research Analyst and Portfolio Manager, writing daily and weekly market analysis and managing a FX and US equity portfolio. Joe was also a contributing writer for industry magazines and publications, including SFO Magazine and the CMT Association. Joe earned a B.S.B.A. in Finance from The American University. He holds the Chartered Market Technician (CMT) designation and is a member of the CFA Institute.

New call-to-action